# Lumexa Imaging Holdings share price today (Lumexa Imaging Holdings, Inc., LMRI)

> Lumexa Imaging Holdings, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. LMRI · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/lmri

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $11.22 (−39.4% in a year)
- Revenue (Jun 2026): $264 M (+5.1% on a year ago)
- Profit (Jun 2026): $2.7 M
- Operating margin: 3.2% (−3.5 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Lumexa Imaging Holdings share price today? Lumexa Imaging Holdings, Inc.'s share price was $11.22 at the close on 3 November 2026. That is 1.4% above its average price over the last 200 trading days. Since its first close in our records, on 12 December 2025, it has traded between $7 and $19, and at that close it sat 36% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 11 months the share price moved −39% while the S&P 500 moved +11%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Lumexa Imaging Holdings pay? Lumexa Imaging Holdings, Inc. pays no dividend. In the last 6 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Lumexa Imaging Holdings on? Lumexa Imaging Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Lumexa Imaging Holdings profitable? Lumexa Imaging Holdings, Inc. earned $2.7 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $47.1 M. That is 1.0% of the quarter's revenue. The same quarter a year earlier lost $7.7 M. ## How much revenue does Lumexa Imaging Holdings make, and is it growing? Lumexa Imaging Holdings, Inc. reported $264 M of revenue in the Jun 2026 quarter, +5.1% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 2 years it has grown 4.6% a year on average. The last full year, FY25, came in at $1.0 B. FY25 revenue was $1.0 B, +7.8% on the year before. Recent pace: the last four quarters grew +5.4% on average, against 4.6% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. ## How much of every $100 of sales does Lumexa Imaging Holdings keep? Lumexa Imaging Holdings, Inc.'s operating margin was 3.2% in the Jun 2026 quarter, 3.5 percentage points lower than the same quarter a year ago. Over the last four quarters it has moved −3.3 percentage points. Across 3 years it has been between −0.6% and 5.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −3.3 percentage points on the year while gross margin changed −0.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Lumexa Imaging Holdings' profit turning into cash? Lumexa Imaging Holdings, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $17.1 M of operating cash against −$47.1 M of profit. After $23.5 M of spending on assets, free cash was −$6.4 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Lumexa Imaging Holdings' cash go? Lumexa Imaging Holdings, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $75.3 M on assets over the last 3 years. Averaged over those years that is 2.5% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $75.3 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Lumexa Imaging Holdings' P/E ratio, and how does it compare with its own history? Lumexa Imaging Holdings, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Lumexa Imaging Holdings, Inc. at 1.1× its FY25 revenue of $1.0 B. The P/E comes back here once profit turns positive. ## Is the Lumexa Imaging Holdings business getting better or worse? Lumexa Imaging Holdings, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Lumexa Imaging Holdings earn on its capital? Lumexa Imaging Holdings, Inc. earned a ROE of −8% in FY25. That is up from a low of −62% in FY23. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −4.6% net margin and 0.58× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −4.6% net margin × 0.58× asset turnover × 3.01× leverage (assets divided by equity) ≈ −8.0% on equity. The margin does its share; borrowing is a big part of it. ## Does Lumexa Imaging Holdings have too much debt? Lumexa Imaging Holdings, Inc. has total debt of $975 M against shareholder equity of $615 M as of Jun 2026, so its debt is 1.59× its equity. Year by year, that ratio went from 6.58 in FY23 to 1.64 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Lumexa Imaging Holdings shareholding pattern? 8.7% of Lumexa Imaging Holdings, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Lumexa Imaging Holdings from balance-sheet trouble? For Lumexa Imaging Holdings, Inc., the Z-score is 0.79. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 0.79 is inside the danger zone, so the balance sheet is a real risk. ## How does Lumexa Imaging Holdings rank in its industry? There is no score against its industry: Lumexa Imaging Holdings, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Lumexa Imaging Holdings compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Lumexa Imaging Holdings in size? Lumexa Imaging Holdings is the 38th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Artivion, Inc., PROCEPT BioRobotics Corporation and CeriBell, Inc. Just below it: SI-BONE, Inc., Integra LifeSciences Holdings Corporation and IRADIMED CORPORATION. ### Medical Devices companies close in size

1. [Artivion, Inc.](https://www.sectoralpha.in/us/stocks/aort) $1.2 billion
2. [PROCEPT BioRobotics Corporation](https://www.sectoralpha.in/us/stocks/prct) $1.2 billion
3. [CeriBell, Inc.](https://www.sectoralpha.in/us/stocks/cbll) $1.1 billion
4. Lumexa Imaging Holdings, Inc. $1.1 billion
5. [SI-BONE, Inc.](https://www.sectoralpha.in/us/stocks/sibn) $1.1 billion
6. [Integra LifeSciences Holdings Corporation](https://www.sectoralpha.in/us/stocks/iart) $1.1 billion
7. [IRADIMED CORPORATION](https://www.sectoralpha.in/us/stocks/irmd) $1 billion

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Seneca Foods Corporation](https://www.sectoralpha.in/us/stocks/senea) $1.1 billion · Packaged Foods
2. [CNB Financial Corporation](https://www.sectoralpha.in/us/stocks/ccne) $1.1 billion · Banks - Regional
3. Lumexa Imaging Holdings, Inc. $1.1 billion
4. [Power Solutions International, Inc.](https://www.sectoralpha.in/us/stocks/psix) $1.1 billion · Specialty Industrial Machinery
5. [Janux Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/janx) $1.1 billion · Biotechnology

## What else do people ask about Lumexa Imaging Holdings? ### What is Lumexa Imaging Holdings's stock price today? Lumexa Imaging Holdings, Inc.'s stock price is $11.22, −39.4% over the past year. The whole company is worth $1.1 B on the market. In the last 52 weeks it traded between $7 to $19; today it is 36% of the way up from the low, 1.4% above its 200-day average (as of 3 November 2026). ### What were Lumexa Imaging Holdings's latest quarterly results? Lumexa Imaging Holdings, Inc. reported revenue of $264 M and net profit of $2.7 M for the Jun 2026 quarter. Earnings per share were $0.03. The operating margin was 3.2%, 3.5 percentage points lower than a year earlier (as of 3 November 2026). ### What is Lumexa Imaging Holdings's market cap? Lumexa Imaging Holdings, Inc.'s market capitalisation is $1.1 B at a stock price of $11.22. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Lumexa Imaging Holdings performing? Lumexa Imaging Holdings, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Lumexa Imaging Holdings's stock price go up? This page does not forecast Lumexa Imaging Holdings, Inc.'s stock price. What it shows instead: the stock price is $11.22. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Lumexa Imaging Holdings in its business cycle? Lumexa Imaging Holdings, Inc.'s FY25 operating margin was 5.0%, against a 3-year range of −0.6% to 5.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 3.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Lumexa Imaging Holdings story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Lumexa Imaging Holdings a stock worth studying right now? What the numbers show: Lumexa Imaging Holdings, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.